Aclaris Therapeutics ACRS Enterprise value

Enterprise value at other companies

IncyteINCY

$18.7B+63.4%

Corvus PharmaceuticalsCRVS

$1.19B+459%

Upstream Bio, Inc.UPB

$298.14M-47.6%

Avalo TherapeuticsAVTX

$886.04M+7,437%

Shattuck Labs, Inc.STTK

$602.2M+28,785%

Cullinan Therapeutics, Inc.CGEM

$1.04B+166%

FAQ

What is Aclaris Therapeutics's enterprise value?

Aclaris Therapeutics (ACRS) reported enterprise value of $721.5M in Q2 2026.

How has Aclaris Therapeutics's enterprise value changed year-over-year?

Aclaris Therapeutics's enterprise value increased by 409.7% year-over-year, from $141.55M to $721.5M.

What is the long-term trend for Aclaris Therapeutics's enterprise value?

Over 5 years (2020 to 2025), Aclaris Therapeutics's enterprise value has grown at a -4.5% compound annual growth rate (CAGR), from $388.23M to $308.28M.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.